您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (12): 53-57.doi: 10.6040/j.issn.1671-7554.0.2016.1106

• 临床医学 • 上一篇    下一篇

CT引导放射性125I粒子植入治疗转移性肝癌的临床疗效

房菲菲,张颖,林琦,袁苑,戴建建,徐瑞彩,耿宝成,韩明勇   

  1. 山东大学附属省立医院东院保健综合(肿瘤)科, 山东 济南 250014
  • 收稿日期:2016-09-03 出版日期:2016-12-10 发布日期:2016-12-10
  • 通讯作者: 韩明勇. E-mail:hanmingyong@sina.com E-mail:hanmingyong@sina.com
  • 基金资助:
    国家自然科学基金(81272351)

Clinical efficacy of CT-guided 125I seed brachytherapy in the treatment of metastatic hepatic carcinoma

FANG Feifei, ZHANG Ying, LIN Qi, YUAN Yuan, DAI Jianjian, XU Ruicai, GENG Baocheng, HAN Mingyong   

  1. Department of Health Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China
  • Received:2016-09-03 Online:2016-12-10 Published:2016-12-10

PDF (PC)

1047

摘要： 目的 观察放射性125I粒子植入治疗转移性肝癌的临床疗效及并发症。 方法 回顾性收集应用125I粒子植入治疗的22例转移性肝癌患者资料,所有患者术前应用治疗计划系统(TPS)制定植入计划,根据TPS计划在CT引导下行肝脏病灶125I粒子植入术,术后行CT检查,将CT图像的DICOM格式图片传送到TPS系统,并进行术后剂量验证。分别于术后1、3、6、9、12个月行CT复查,进行临床疗效及并发症评价。 结果 22例患者病灶总数为27个,中位肿瘤最长径3.4 cm(1.0~7.4 cm),病灶植入粒子数4~87颗,粒子活度1.85×107~2.96×107 Bq(0.5~0.8 mCi)。术后1个月,CR 11例,PR 6例,SD 5例,PD 5例,局控率(CR+PR+SD)为81.5%。术后3、6、9、12个月局控率分别为78.9%、76.9%、77.8%、66.7%。中位随访时间6个月(1~14个月),生存13例,死亡9例,中位生存时间12个月。粒子植入术后疼痛缓解率91.7%。术中出血7例(31.8%),恶心/呕吐3例(13.6%),术后发热1例(4.5%),粒子移位2例(9.1%)。 结论 125I粒子植入术治疗转移性肝癌疗效确切,并发症少,是治疗肝脏恶性肿瘤的有效方法之一。

关键词: 125I粒子, 并发症, 局控率, 肝脏肿瘤

Abstract: Objective To evaluate the efficacy and complications of CT-guided permanent 125I seed interstitial brachytherapy in the treatment of metastatic hepatic carcinoma. Methods A total of 22 patients with metastatic hepatic carcinoma were enrolled. A treatment plan was made for each patient using a computerized treatment planning system(TPS)to determine the dose of radioactive seeds implanted and the site. With CT guidance, 125I seeds were placed into the metastatic sites in the liver. After operation, CT scan was performed to verify the position and intensity of 125I seeds. CT scan was performed 1 month, 3, 6, 9 and 12 months after operation to evaluate the local control rate of tumor and complications. Results Altogether 27 liver lesions were included in this study. The median longest diameter was 3.4 cm(1.0-7.4 cm). The number of 125I seeds was 4-87. The activity was 1.85×107-2.96×107 Bq(0.5-0.8 mCi). One month after operation, 11 patients gained complete remission(CR), 6 partial remission(PR), 5 stable disease(SD)and 5 progression of disease(PD). The local tumor control rate 1 month, 3, 6, 9 and 12 months after operation was 81.5%, 78.9%, 76.9%, 77.8% and 66.7%, respectively. During the follow-up of 1-14 months(median 6 months), 13 patients survived and 9 died. The median survival time for all patients was 12 months. The rate of pain relief was 91.7%. Minor complications were bleeding ［31.8%(7/22)］, nsusea/vomiting ［13.6%(3/22)］, 山 东 大 学 学 报 (医 学 版)54卷12期 -房菲菲,等.CT引导放射性125I粒子植入治疗转移性肝癌的临床疗效 \=- fever［4.5%(1/22)］ and seed displacement ［9.1%(2/22)］. Conclusion CT-guided 125I seed brachytherapy is a safe and effective treatment for metastatic hepatic carcinoma with few complications.

Key words: 125I seed, Complications, Local control rate, Liver malignancies

中图分类号: 

  • R735.7
[1] 傅志强, 周琪, 侯克柱, 等. 经皮肝穿刺微波热凝治疗转移性肝癌的疗效评价[J]. 中华临床医师杂志, 2016, 10(8): 1071-1073. FU Zhiqiang, ZHOU Qi, HOU Kezhu, et al. Therapeutic evaluation of percutaneous microwave coagulation therapy for metastatic hepatic carcinoma[J]. Chinese Journal of Clinicians, 2016, 10(8): 1071-1073.
[2] Yao L, Jiang Y, Jiang P, et al. CT-guided permanent 125I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy[J]. Brachytherapy, 2015, 14(5): 662-669.
[3] Li C, Zhang F, Zhang W, et al. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(11):1633-1640.
[4] Gao F, Li C, Gu Y, et al. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82(2):70-75.
[5] Keyes M, Morris WJ, Spadinger I, et al. Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program[J]. Brachytherapy, 2013, 12(4): 343-355.
[6] Zhang L, Lu J, Wang Z, et al. Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors[J]. Onco Targets Ther, 2015, 9: 7-12. doi: 10.2147/OTT.S95410.
[7] Xiang Z, Mo Z, Li G, et al. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments[J]. Oncotarget, 2016, 7(14): 18384-18393.
[8] Huo X, Wang H, Yang J, et al. Effectiveness and safety of CT-guided 125I seed brachytherapy for postoperative locoregional recurrence in patients with none-small cell lung cancer[J]. Brachytherapy, 2016, 15(3): 370-380.
[9] Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy[J]. Ann Oncol, 2013, 24(3): 668-673.
[10] Wang Z, Lu J, Liu L, et al.Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma[J]. Radiat Oncol, 2011, 6: 138. doi: 10.1186/1748-717X-6-138.
[11] Zuber S, Weiß S, Baaske D, et al. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review[J]. Radiat Oncol, 2015, 10: 49. doi: 10.1186/s13014-015-0349-0.
[12] Wang J, Yuan H, Ma Q, et al. Interstitial 125I seeds implantation to treat spinal metastatic and primary paraspinal malignancies[J]. Med Oncol, 2010, 27(2): 319-326.
[13] 曲昂, 王俊杰. 125I粒子置入治疗非小细胞肺癌癌症进展现状[J]. 癌症进展, 2013, 11(1): 53-55.
[14] 柳晨, 王俊杰, 孟娜, 等. CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤的价值[J]. 中国脊柱脊髓杂志, 2011, 21(3): 226-229. LIU Chen, WANG Junjie, MENG Na, et al. CT-guide interstitial iodine-125 seed implantation for metastatic spine tumor[J]. Chinese Journal of Spine and Spinal Cord, 2011, 21(3): 226-229.
[15] Li J, Xie Q, Wang W, et al. CT-guided implantation of 125I seeds(permanent brachytherapy)for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients[J]. Brachytherapy, 2016, 15(2): 224-230.
[16] 冉琳, 陈鹏, 彭勤中. 经皮超声引导下125I粒子植入治疗肝脏肿瘤[J]. 中国超声医学杂志, 2010, 26(6): 520-523. RAN Lin, CHEN Peng, PENG Qinzhong, et al. Radioactive seed 125I Implantion in Treatment of Liver tumor with Ultrasonographic Guidance[J]. Chinese Journal of Ultrasound in Medicine, 2010, 26(6): 520-523.
[17] Sharma DN, Thulkar S, Sharma S, et al. High-dose-rate interstitial brachytherapy for liver metastases: first study from India[J]. J Contemp Brachytherapy, 2013, 5(2): 70-75.
[18] 张福君, 吴沛宏, 焦德超, 等. CT导向125I粒子植入治疗肝癌肝转移术后复发/转移瘤的近中期疗效[C]. 中国(第七届)肿瘤微创治疗学术大会暨世界影响导引下肿瘤微创治疗学会成立筹备大会论文汇编. 2011.
[19] Zhongmin W, Yu L, Fenju L, et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer[J]. Eur Radiol, 2010, 20(7): 1786-1791.
[20] Zhang L, Chen LH, Wang J, et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
[1] 董恣豪,刘喆,王浩,于辰曦,杨光,丰浩田. 髋关节镜下关节囊不同切开方式早期术后并发症[J]. 山东大学学报 (医学版), 2026, 64(5): 83-87.
[2] 史潇兮,辛世杰. 腹主动脉瘤的开放手术[J]. 山东大学学报 (医学版), 2024, 62(9): 26-29.
[3] 王瑞霞,苏童,赵淑磊. 内镜逆行性胆胰管造影术罕见并发症-胆道支架无法拔除1例[J]. 山东大学学报 (医学版), 2024, 62(2): 113-115.
[4] 李红梅,蔡敏,周立,姚欣雨,刘力. 不同膈肌超声功能指标在腹部手术后肺部并发症中的预测价值[J]. 山东大学学报 (医学版), 2024, 62(10): 115-124.
[5] 徐荣坤,王连雷,原所茂,田永昊,刘新宇. 腰椎术中腹主动脉损伤1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(6): 121-124.
[6] 穆彦熹,李金洲,陈康,梁红英,姚亚龙,汪文杰,陈晓. 443例胃癌根治术后发生肺部并发症的危险因素[J]. 山东大学学报 (医学版), 2023, 61(4): 37-41.
[7] 王艳莉,冯晔,周秀耕,杨跃,吴楠,方玉,阎石,李少雷,吕超,韩超,杜松涛. 33例食管癌患者围术期补充乳清蛋白粉对术后并发症的预防作用[J]. 山东大学学报 (医学版), 2022, 60(3): 64-70.
[8] 林均馨,刘玉江,刘培来,万连平,张鹏,杜建春,刘泽淼,孔杰,高升焘. 固定平台单髁术后胫骨假体周围骨折2例[J]. 山东大学学报 (医学版), 2022, 60(3): 96-99.
[9] 张建平,罗莺儿. 抗凝药物在反复不良妊娠治疗中的应用进展[J]. 山东大学学报 (医学版), 2021, 59(8): 14-19.
[10] 邹俊逸,张辉,张歆杰,李子佳,许明雷,王东. 110例原位心脏移植临床经验[J]. 山东大学学报 (医学版), 2021, 59(8): 86-91.
[11] 罗应舒,李宾,许昌芹,姜军梅,许洪伟. 240例上消化道黏膜下肿瘤内镜治疗的疗效及并发症评估[J]. 山东大学学报 (医学版), 2021, 59(3): 74-80.
[12] 郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72-76.
[13] 程瑞林,黄政,李正勋,张宁,胡勇,徐文鹏. 小切口腓肠肌腱翻瓣术治疗5例陈旧性跟腱断裂[J]. 山东大学学报 (医学版), 2020, 58(6): 92-96.
[14] 吴成威,孙博实,周军德,蒋天明,迟强. 术前口服多糖溶液对结直肠癌患者术后胰岛素抵抗的关联性研究[J]. 山东大学学报 (医学版), 2019, 57(9): 48-53.
[15] 王冰. 腰椎完全内镜经椎板间入路技术的临床教程[J]. 山东大学学报 (医学版), 2019, 57(5): 23-29.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发